Recent Knowledge in favor of remdesivir (GS-5734) as a therapeutic
option for the COVID-19 infections
Abstract
The management of SARS-CoV 2 has not yet been clearly determined and is
based on the potential therapeutics evaluated during the SARS-CoV and
MERS-CoV epidemics. Although there is currently no antiviral treatment
for the treatment of human coronavirus infections, the preclinical
results with remdesivir (RDV) are promising. This antiviral is
identified as a drug option to be evaluated against COVID-19, based on
data on its activity in vitro and in vivo on the coronaviruses MERS-CoV
and SARS-CoV. Today it is used to fight coronavirus. It acts on COVID-19
by interfering with key stages in the replication cycle of the virus.